The doctor administering the Ph2 Covid long-hauler
Post# of 148185
(Total Views: 933)
Posted On: 11/19/2020 4:45:05 PM
The doctor administering the Ph2 Covid long-hauler trial is also its best spokesperson. Sounds like a slam dunk to me.
Doctor who was also COVID-19 patient
Dr. Chris Recknor, a Gainesville internist who runs one of the six sites for the leronlimab clinical trial, is also a COVID-19 survivor.
He first got sick in April, starting with an intense headache. Then, he started bumping into things and saw floaters in his eyes. Those aren’t the most common coronavirus symptoms, but he knew something wasn’t right and decided to get tested to, if nothing else, rule out the infectious virus. The test was positive.
His condition worsened to the point where he thought he might have a heart attack. He ended up in ER at Northeast Georgia Medical Center three times and was twice admitted for overnight stays.
“I felt like my heart was pumping so hard, it felt like it was coming out of my ears,” he said.
His physician at the hospital obtained “compassionate use” permission from the Food and Drug Administration to prescribe leronlimab.
Researchers think that the drug may work by calming the aggressive immune response called the “cytokine storm,” which occurs in ill COVID-19 patients.
Recknor said he felt better within two days after getting the medication and has fully recovered.
“The only way I can explain it is, it was like it felt like I had 1,000 cups of coffee,” said Recknor. “And then after the medicine, it was like a relaxing time on the beach. A couple days after the medicine, I was back to doing everything normal. I knew there were other people like me having crazy symptoms.”
So Recknor, who is a clinical trialist and founder of the Center for Advanced Research & Education, contacted the drug company and offered to run one of the country’s clinical trial sites. Those in the trial are post-COVID survivors looking for relief after several weeks of battling the illness.
Doctor who was also COVID-19 patient
Dr. Chris Recknor, a Gainesville internist who runs one of the six sites for the leronlimab clinical trial, is also a COVID-19 survivor.
He first got sick in April, starting with an intense headache. Then, he started bumping into things and saw floaters in his eyes. Those aren’t the most common coronavirus symptoms, but he knew something wasn’t right and decided to get tested to, if nothing else, rule out the infectious virus. The test was positive.
His condition worsened to the point where he thought he might have a heart attack. He ended up in ER at Northeast Georgia Medical Center three times and was twice admitted for overnight stays.
“I felt like my heart was pumping so hard, it felt like it was coming out of my ears,” he said.
His physician at the hospital obtained “compassionate use” permission from the Food and Drug Administration to prescribe leronlimab.
Researchers think that the drug may work by calming the aggressive immune response called the “cytokine storm,” which occurs in ill COVID-19 patients.
Recknor said he felt better within two days after getting the medication and has fully recovered.
“The only way I can explain it is, it was like it felt like I had 1,000 cups of coffee,” said Recknor. “And then after the medicine, it was like a relaxing time on the beach. A couple days after the medicine, I was back to doing everything normal. I knew there were other people like me having crazy symptoms.”
So Recknor, who is a clinical trialist and founder of the Center for Advanced Research & Education, contacted the drug company and offered to run one of the country’s clinical trial sites. Those in the trial are post-COVID survivors looking for relief after several weeks of battling the illness.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼